Key result
An integrated pre-clinical strategy incorporating in vitro, in vivo, and in silico techniques is recommended to identify and mitigate cardiac sodium channel blockade liabilities early in drug discovery.
An integrated pre-clinical framework combining in vitro, in vivo, and in silico techniques is essential for early detection and mitigation of off-target cardiac sodium channel (hNav1.5) liabilities in drug candidates.
Answers are grounded in this paper and cite their sources.
May accelerate early cardiotoxicity detection in discovery; leaves open prospective validation of integrated hNav1.5 strategies.
The human cardiac sodium channel (hNav1.5, encoded by the SCN5A gene) is critical for action potential generation and propagation in the heart. Drug-induced sodium channel inhibition decreases the rate of cardiomyocyte depolarization and consequently conduction velocity and can have serious implications for cardiac safety. Genetic mutations in hNav1.5 have also been linked to a number of cardiac diseases. Therefore, off-target hNav1.5 inhibition may be considered a risk marker for a drug candidate. Given the potential safety implications for patients and the costs of late stage drug development, detection, and mitigation of hNav1.5 liabilities early in drug discovery and development becomes important. In this review, we describe a pre-clinical strategy to identify hNav1.5 liabilities that incorporates in vitro, in vivo, and in silico techniques and the application of this information in the integrated risk assessment at different stages of drug discovery and development.
No takes yet. Share an insight, caveat, or question.
Erdemli et al. (2012) conducted a review in Drug-induced cardiac sodium channel (hNav1.5) inhibition. An integrated pre-clinical strategy incorporating in vitro, in vivo, and in silico techniques is recommended to identify and mitigate cardiac sodium channel blockade liabilities early in drug discovery.
Synapse has enriched 10 related papers. Consider them for comparative context: